Pipeline Therapeutics and Janssen enter into a global licensing deal for PIPE-307. The deal is valued up to $1B USD.

The generative AI drug company ramps up its internal pipeline and R&D portfolio, tapping into European markets, talent, and tech.

bsci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. He

VIENNA, AUSTRIA, January 31, 2022 -- Ribbon Biolabs, the DNA synthesis company, today announced the successful close of EUR 18 million in...

VANCOUVER, Wash., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company ...

AbSci Corp. ABSI, has set terms of its initial public offering, which could value the Washington-based provider of an artificial...

AbSci, which provides a platform for the discovery and development of proteins and biologics, announced terms for its IPO on Thursday....

https://seekingalpha.com/news/3711566-biotech-discovery-company-absci-files-for-ipo Absci Corp., a synthetic biology company whose...

https://www.globenewswire.com/news-release/2021/06/14/2246385/0/en/Landos-Biopharma-Announces-Positive-Outcome-of-End-of-Phase-2-Meeting-...

Totient, a Helicase Venture portfolio company, has been acquired by AbSci, a synthetic biology company unlocking the potential of...

SAN DIEGO, March 2, 2021 – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of...

SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of...

Landos is based upon the work of CEO Josep Bassaganya-Riera, Ph.D., a serial entrepreneur and Virginia Tech professor who outlined the...

PIPE-505 is the first small molecule developed specifically for the treatment of sensorineural hearing loss (SNHL) associated with ...